Compare Core Scientific Inc (CORZ) vs TransMedics Group Inc (TMDX) Price & Performance

Core Scientific (CORZ) trades at $15.41, down 3.32% today, with bearish technical signals and significant fundamental challenges. The company reported a net loss of $288.62 million in 2025 with negative profit margins, though revenue grew to $319.02 million. Analyst sentiment remains overwhelmingly positive with 86% buy ratings and a $32.75 consensus price target, while recent news highlights the company's pivot toward AI data center operations and insider buying activity.

Despite strong analyst support, CORZ faces substantial execution risks in its AI infrastructure transition amid persistent losses and negative cash flow. The stock's current price near key support levels presents potential upside if the company can achieve profitability, but investors should weigh the high-risk profile against the optimistic Wall Street projections.

TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.

The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.